Biotech Giants and Damon Runyon Scientists Convene in Cambridge to Advance the 2026 Accelerating Cancer Cures Initiative

Damon Runyon and Amgen leaders meet in Cambridge to fast-track cancer therapeutics through a multi-million-dollar industry-academic partnership.

By: AXL Media

Published: Mar 28, 2026, 11:13 AM EDT

Source: Information for this report was sourced from Damon Runyon Cancer Research Foundation

A Multi-Million Dollar Bridge Between Lab and Clinic

The 2026 Accelerating Cancer Cures Research Symposium, hosted by Amgen in Cambridge, Massachusetts, underscored a decade-long commitment to transforming raw scientific data into life-saving medical interventions. Since its inception in 2011, this multi-million-dollar collaborative effort led by the Damon Runyon Cancer Research Foundation has sought to cultivate a specialized class of clinical investigators capable of navigating both academic and industrial landscapes. By bringing together representatives from global entities such as AbbVie, Novartis, and Pfizer alongside university researchers, the initiative aims to dismantle the silos that traditionally slow the pace of drug development.

Cultivating a Pipeline of Scientific Excellence

During the opening proceedings, James Bradner, MD, who serves as Executive Vice President of Research and Development at Amgen, characterized the Damon Runyon cohort as an essential talent pipeline for the biopharmaceutical industry. Drawing a comparison to professional sports, Dr. Bradner referred to the organization as the triple-A team for Amgen, noting that the scientists selected for support represent a unique combination of scholarly depth and professional bravery. This strategic relationship ensures that the most promising minds in oncology are integrated into environments where their research into cancer genomics can be scaled and commercialized for global patient populations.

Decoding the Molecular Basis of Precision Medicine

A significant portion of the symposium featured technical updates from researchers including Mark Yarmarkovich, PhD, and Ziyang Zhang, PhD, who are currently investigating the fine-grained molecular mechanisms of gene expression. Their work is central to the shift toward targeted therapies, which move away from broad-spectrum treatments in favor of interventions tailored to specific genetic signatures. By achieving a more precise understanding of how cancer interacts with the human genome, these scientists are laying the groundwork for the next generation of diagnostics that could identify malignancies long before they become symptomatic.